Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B

키워드

참고문헌 (80)

1. 김석배, "건강검진 수진자를 대상으로 한 충남 서북부 지역의 바이러스 간염 표지자 양성률 및 간수치 이상에 관한 연구", 대한소화기학회지, 53(6), pp.355~360 (2009), 대한소화기학회
2. European Association for the Study of the Liver, "EASL Clinical Practice Guidelines: management of chronic hepatitis B", J Hepatol, 50, pp.227~242 (2009)
3. Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
4. DiBisceglie A, "Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside treated hepatitis B patients", Hepatology, 44(Suppl 1), pp.230A~ (2006)
5. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
6. Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load", Gastroenterology, 130, pp.678~686 (2006)
7. Zoulim F, "Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection", Antiviral Res, 64, pp.1~15 (2004)
8. Dienstag JL, "A preliminary trial of lamivudine for chronic hepatitis B infection", N Engl J Med, 333, pp.1657~1661 (1995)
9. Dienstag JL, "Lamivudine as initial treatment for chronic hepatitis B in the United States", N Engl J Med, 341, pp.1256~1263 (1999)
10. Lai CL, "A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group", N Engl J Med, 339, pp.61~68 (1998)
11. Schalm SW, "Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial", Gut, 46, pp.562~568 (2000)
12. Chang TT, "Four years of lamivudine treatment in Chinese patients with chronic hepatitis B", J Gastroenterol Hepatol, 19, pp.1276~1282 (2004)
13. Yao GB, "A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China", J Dig Dis, 10, pp.131~137 (2009)
14. Hadziyannis SJ, "Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B", Hepatology, 32(4 Pt 1), pp.847~851 (2000)
15. Lok AS, "Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy", Hepatology, 32, pp.1145~1153 (2000)
16. Fung SK, "Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B", J Viral Hepat, 11, pp.432~438 (2004)
17. Heon Ju Lee, "Prevention by Lamivudine of Hepatocellular Carcinoma in Patients Infected with Hepatitis B Virus", Gut and Liver, 1(2), pp.151~158 (2007), 거트앤리버 발행위원회
18. Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", N Engl J Med, 351, pp.1521~1531 (2004)
19. Nikolaidis N, "Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive", HBeAg-negative chronic hepatitis B, 2005, pp.19, 321~326
20. Dienstag JL, "Durability of serologic response after lamivudine treatment of chronic hepatitis B", Hepatology, 37, pp.748~755 (2003)
21. Lee KM, "Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion", J Viral Hepat, 9, pp.208~212 (2002)
22. 정영화, "Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea", HEPATOLOGY, 32(4 Pt 1), pp.803~806 (2000), JOHN WILEY & SONS INC
23. Cha CK, "Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B", J Med Virol, 81, pp.417~424 (2009)
24. Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B", Gastroenterology, 125, pp.1714~1722 (2003)
25. Yuen MF, "Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy", Hepatology, 34(4 Pt 1), pp.785~791 (2011)
26. Marcellin P, "Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B", N Engl J Med, 348, pp.808~816 (2003)
27. Marcellin P, "Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B", Hepatology, 48, pp.750~758 (2008)
28. Hadziyannis SJ, "Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B", N Engl J Med, 352, pp.2673~2681 (2005)
29. Hadziyannis SJ, "Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B", N Engl J Med, 348, pp.800~807 (2003)
30. Hadziyannis SJ, "Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years", Gastroenterology, 131, pp.1743~1751 (2006)
31. Lim SG, "Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B", Aliment Pharmacol Ther, 26, pp.1419~1428 (2007)
32. Angus P, "Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase", Gastroenterology, 125, pp.292~297 (2003)
33. Villeneuve JP, "Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient", J Hepatol, 39, pp.1085~1089 (2003)
34. Westland CE, "Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B", Hepatology, 38, pp.96~103 (2003)
35. Fung SK, "Virologic response and resistance to adefovir in patients with chronic hepatitis B", J Hepatol, 44, pp.289~290 (2006)
36. Lee YS, "Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy", HEPATOLOGY, 43(6), pp.1385~1391, JOHN WILEY & SONS INC
37. Lee JM, "Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B", Antivir Ther, 15, pp.235~241 (2010)
38. Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
39. Leung N, "Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir", Hepatology, 49, pp.72~79 (2009)
40. Lai CL, "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 354, pp.1011~1020 (2006)
41. Shim JH, "Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis", J Hepatol, 52, pp.176~182 (2010)
42. 한광협, "Entecavir therapy for up to 96 weeks in patients with HBeAg-Positive chronic hepatitis B", GASTROENTEROLOGY, 133, pp.1437~1444, W B SAUNDERS CO-ELSEVIER INC
43. Shouval D, "Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy", J Hepatol, 50, pp.289~295 (2009)
44. Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)
45. Fournier C, "Antiviral therapy of chronic hepatitis B: prevention of drug resistance", Clin Liver Dis, 11, pp.869~892 (2007)
46. 김동준, "Telbivudine versus lamivudine in patients with chronic hepatitis B", NEW ENGLAND JOURNAL OF MEDICINE, 357(25), pp.2576~2588, MASSACHUSETTS MEDICAL SOC
47. 황성규, "2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B", GASTROENTEROLOGY, 136, pp.486~495, W B SAUNDERS CO-ELSEVIER INC
48. Zeuzem S, "Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B", J Hepatol, 51, pp.11~20 (2009)
49. 문영명, "한국인 만성 B형간염 환자에 대한 텔비부딘의 효능 및 안전성", Clinical and Molecular Hepatology, 13(4), pp.503~512 (2007), 대한간학회
50. Lok AS, "Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management", Hepatology, 46, pp.254~265 (2007)
51. Marcellin P, "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B", N Engl J Med, 359, pp.2442~2455 (2008)
52. Heathcote EJ, "Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B", Gastroenterology, 140, pp.132~143 (2011)
53. Liaw YF, "Tenofovir disoproxil fumarate (TDF), emtricitabine", TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease, 2011, pp.53, 62~72
54. van Bömmel F, "Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside", nucleotide analogues, 2010, pp.51, 73~80
55. Sheldon J, "Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir", Antivir Ther, 10, pp.727~734 (2005)
56. Amini-Bavil-Olyaee S, "The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains", Hepatology, 49, pp.1158~1165 (2009)
57. Balakrishna Pai S, "Inhibition of hepatitis B virus by a novel L-nucleoside, 2’-fluoro-5-methyl-beta-L-arabinofuranosyl uracil", Antimicrob Agents Chemother, 40, pp.380~386 (1996)
58. Chu CK, "Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent", Antivir Ther, 3(Suppl 3), pp.113~121 (1998)
59. Ma T, "Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents", J Med Chem, 39, pp.2835~2843 (1996)
60. Yoo BC, "Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B", HEPATOLOGY, 45, pp.1172~1178, JOHN WILEY & SONS INC
61. George KK Lau, "Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study", Clinical and Molecular Hepatology, 16(3), pp.315~320 (2010), 대한간학회
62. 김인희, "Treatment Outcomes of Clevudine versus Lamivudine at Week 48 in Naive Patients with HBeAg Positive Chronic Hepatitis B", Journal of Korean Medical Science, 25(5), pp.738~745 (2010), 대한의학회
63. Yoo BC, "Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression", HEPATOLOGY, 46(4), pp.1041~1048, JOHN WILEY SONS INC
64. Tak WY, "Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy", J Hepatol, 53, pp.261~266 (2010)
65. Kim HJ, "Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B", Liver Int, 30, pp.834~840 (2010)
66. Kwon SY, "Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients", J Virol, 84, pp.4494~4503 (2010)
67. 이헌주, "만성 B형간질환에서 핵산유사체 치료경험이 없는 환자와 라미부딘 경험자에서의 클레부딘 치료", Clinical and Molecular Hepatology, 15(2), pp.179~192 (2009), 대한간학회
68. Chang TT, "Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B", Hepatology, 51, pp.422~430 (2010)
69. Suzuki F, "Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients", J Gastroenterol Hepatol, 52, pp.892~898 (2010)
70. Yuen MF, "Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy", Antivir Ther, 14, pp.679~685 (2009)
71. Rapti I, "Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B", Hepatology, 45, pp.307~313 (2007)
72. Lampertico P, "Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine", Hepatology, 42, pp.1414~1419 (2005)
73. Lampertico P, "Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients", Gastroenterology, 133, pp.1445~1451 (2007)
74. 조영주, "라미부딘 내성 만성 B형간염 환자에서 아데포비어 단독요법 후 라미부딘 추가투여의 효과", 대한소화기학회지, 56(2), pp.83~89 (2010), 대한소화기학회
75. van Bömmel F, "Tenofovir shows limited efficacy in treatment of HBV infections resistant against adefovir", Hepatology, 46(Suppl 1), pp.664A~ (2007)
76. Patterson SJ, "Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B", Gut, 60, pp.247~254 (2011)
77. Cho SW, "Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance", J Viral Hepat, 17, pp.171~177 (2010)
78. Shim JH, "Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone", Hepatology, 50, pp.1064~1071 (2009)
79. Heo NY, "Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir", J Hepatol, 53, pp.449~454 (2010)
80. Yang HJ, "Lamivudine and adefovir dipivoxil versus entecavir 1.0 mg alone for the treatment of adefovir-resistant mutation which deveolpoed during sequential adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B", Korean J Hepatol, 15(Suppl 3), pp.S50~ (2009)

관련 논문AI추천